TestaTesta Center by STUNS -- to continue building on Uppsala's area of strength and create growth in the region: Cluster support and business networks primarily benefiting SMEs

TestaTesta Center by STUNS -- to continue building on Uppsala's area of strength and create growth in the region

The past year has been marked by the Covid19 pandemic, bringing many well-functioning companies with development and growth ambitions to a new reality, focusing on identifying and developing new cost-effective solutions and rethinking business models, distribution channels and markets for survival. Companies that are responsive and adapt to the new situation are better placed for continued long-term competitiveness. With the current pandemic, crisis awareness has also increased and the need for crisis preparedness has been put on the agenda in society. By strengthening expertise in biological processes, Sweden's long-term opportunity to develop and produce biological medicines such as vaccines in the future pandemic is ensured. This project aims to provide more innovation companies in biology, technology and digitalisation with increased opportunities to test and verify their innovation in a genuine bioproduction environment. As a result, they can bridge the gap from research results to industrialisation in a cost-effective way and thus also reduce the negative impact that bioprocess in particular has on the environment. At the same time, this contributes to support companies that cannot receive or qualify for the support packages launched earlier during the pandemic. The main objective of the project is to create a long-term system transformation for how to industrialise biological projects and to reach out to technical and digital companies that will contribute to developing the innovation environment and themselves verify their products and services for a new market. Both aim to lift already viable companies to emerge even stronger from the pandemic.

EU Calls: Credit © European Union, 1998-2024 under <a href="http://creativecommons.org/licenses/by/4.0/">CC BY 4.0 licence</a>